» Articles » PMID: 36903561

Rational Computational Approaches in Drug Discovery: Potential Inhibitors for Allosteric Regulation of Mutant Isocitrate Dehydrogenase-1 Enzyme in Cancers

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 Mar 11
PMID 36903561
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in homodimeric isocitrate dehydrogenase (IDH) enzymes at specific arginine residues result in the abnormal activity to overproduce -2 hydroxyglutarate (-2HG), which is often projected as solid oncometabolite in cancers and other disorders. As a result, depicting the potential inhibitor for -2HG formation in mutant IDH enzymes is a challenging task in cancer research. The mutation in the cytosolic IDH1 enzyme at R132H, especially, may be associated with higher frequency of all types of cancers. So, the present work specifically focuses on the design and screening of allosteric site binders to the cytosolic mutant IDH1 enzyme. The 62 reported drug molecules were screened along with biological activity to identify the small molecular inhibitors using computer-aided drug design strategies. The designed molecules proposed in this work show better binding affinity, biological activity, bioavailability, and potency toward the inhibition of -2HG formation compare to the reported drugs in the in silico approach.

Citing Articles

Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations.

Zhang W, Bai H, Wang Y, Wang X, Jin R, Guo H Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543123 PMC: 10976062. DOI: 10.3390/ph17030336.

References
1.
Zheng Q, Chen Z, Wan H, Tang S, Ye Y, Xu Y . Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors. Bioorg Med Chem Lett. 2018; 28(23-24):3808-3812. DOI: 10.1016/j.bmcl.2018.07.002. View

2.
Oermann E, Wu J, Guan K, Xiong Y . Alterations of metabolic genes and metabolites in cancer. Semin Cell Dev Biol. 2012; 23(4):370-80. PMC: 3351496. DOI: 10.1016/j.semcdb.2012.01.013. View

3.
Friesner R, Banks J, Murphy R, Halgren T, Klicic J, Mainz D . Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004; 47(7):1739-49. DOI: 10.1021/jm0306430. View

4.
Cohen A, Holmen S, Colman H . IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep. 2013; 13(5):345. PMC: 4109985. DOI: 10.1007/s11910-013-0345-4. View

5.
Thamim M, Thirumoorthy K . Chiral discrimination in a mutated IDH enzymatic reaction in cancer: a computational perspective. Eur Biophys J. 2020; 49(7):549-559. DOI: 10.1007/s00249-020-01460-x. View